ArticleDrug design, development and therapy2026
An Exploratory Analysis of Potential Core Targets and Signaling Pathways Linking Dexmedetomidine to Diabetes Insipidus: Integration of FAERS Pharmacovigilance Data, Network Toxicology and Clinical Transcriptomics.
Article in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Dexmedetomidine is widely used for clinical sedation, while clinical data suggest a potential correlation between its administration and diabetes insipidus. This exploratory study aimed to characterize molecular correlates linking dexmedetomidine and diabetes insipidus via multiomics and pharmacovigilance analysis. Methods: FAERS data (2004-2024) were mined for disproportionality analysis to screen suggestive association signals. Network toxicology predicted shared targets of dexmedetomidine and diabetes insipidus, followed by GO/KEGG enrichment, PPI network construction and molecular docking. Transcriptome sequencing of 10 treated patients preliminarily validated bioinformatic correlations. Results: A strong suggestive association signal was detected (ROR=471.47). A total of 105 overlapping targets were screened, among which IL6, IL10, INS, IL1B, AKT1 and IFNG served as core correlated hub genes. Docking confirmed stable binding between dexmedetomidine and these proteins. Enrichment revealed enriched MAPK cascade, kinase activity and PI3K/AKT pathways, which may correlate with abnormal AQP2 function. Transcriptomics identified differential expression of inflammation-immune genes after infusion, consistent with predicted molecular correlations. Conclusion: This study combined FAERS pharmacovigilance analysis, network toxicology, molecular docking and transcriptome sequencing to explore potential mechanisms of dexmedetomidine-induced diabetes insipidus. FAERS data mining uncovered a robust adverse signal, indicating a strong correlation between dexmedetomidine and diabetes insipidus for clinical reference. Six hub genes and PI3K/AKT, MAPK pathways may be associated with this side effect. These findings facilitate high-risk population management and individualized sedation, and supply molecular candidates for future validation studies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.